Zymeworks Announces Participation in Upcoming Investor Conference

Rhea-AI Summary

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2023. Management will hold one-on-one meetings and a fireside chat on November 29 at 4:45 pm EST. Presentations and webcasts will be available on Zymeworks’ website. The company focuses on developing multifunctional biotherapeutics, with lead candidate zanidatamab targeting HER2 in clinical trials.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

• 5^th Annual Evercore ISI HealthCONx Conference. Zymeworks’ management will participate in one-on-one meetings on November 29^th – December 1^st and a fireside chat on November 29^th at 4:45 pm Eastern Standard Time (EST).

All presentations and webcasts will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005045/en/

Investor Inquiries:

Jack Spinks

(604) 678-1388

ir@zymeworks.com



Media Inquiries:

Diana Papove

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

What is the schedule for Zymeworks at the 5th Annual Evercore ISI HealthCONx Conference?

Zymeworks will participate in one-on-one meetings from November 29 to December 1, 2023, and a fireside chat on November 29 at 4:45 pm EST.

Where can I find Zymeworks' presentations and webcasts?

Presentations and webcasts can be found on Zymeworks' official website.

What is Zymeworks' lead clinical candidate?

Zymeworks' lead clinical candidate is zanidatamab, targeting HER2 in solid tumors.

What is the primary focus of Zymeworks Inc.?

Zymeworks focuses on the discovery and development of next-generation multifunctional biotherapeutics.